As per the report published, the Antifungal Drugs Market size in Europe USD 3.4 billion in 2020. It is projected to grow with a CAGR of 3.4% and worth USD 4.01 billion by 2025. In the following few years, the market is poised to grow hugely with the rising population globally.
Antifungal drugs are commonly used to cure fungal infections due to unclean, unhygienic, and damp environments. The invasion of epithelial tissue by microscopic organisms leads to fungal infections. Systemic fungal infections are caused due to indigestion or inhalation of spores, leading to fungal pneumonia, and diseases like candidiasis, meningitis, mucormycosis, etc., are caused by opportunistic fungus. Although most fungal infections and diseases are commonly non-lethal, they are very uncomfortable to the host, and their common occurrence is responsible for the rising antifungal drugs market. Antifungal drugs work via various mechanisms by inhibiting cell wall formation, cell membrane disruption, and cell division.
The major factors driving the market are increasing awareness of fungal infections with the growing incidence rate of antifungal infections all over the world, increasing government and corporate funds in the industry. The development of public-private partnerships in the pharmaceutical industry and the rising popularity of over-the-counter antifungal drugs for dermal infections are vastly responsible for the growing antifungal drug market size. Also, the rising population with a weak immune system, in whom fungal infections are much more than average, will drive the market. The high prevalence of conventional drugs used for the treatment of fungal infections is significantly restraining market growth.
The cost of drugs and their effectiveness in treatments remain the challenges for the market.
This research report on the European Antifungal Drugs Market has been segmented and sub-segmented into the following categories:
By Drug Type:
By Therapeutic Indications:
By Application:
By Country:
Geographically, Europe commands a second-largest share of the global antifungal drugs market next to North America. Germany contributes to the major share of the European antifungal drugs market. Growing technological advancements in the European region will drive the market.
Notable companies operating in the European Antifungal drugs market are Alternaria, Pfizer, Novartis, Sanofi-Aventis, Merck & Co., Asperqillus, Kramer Laboratories, Bayer Healthcare, Enzon Pharmaceuticals, Glaxosmithkline Gilead, and Abbott Laboratories.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Drug Type
5.1.1 Echinocandins
5.1.2 Azoles
5.1.3 Polyenes
5.1.4 Allylamines
5.1.5 Others
5.2 By Therapeutic Indications
5.2.1 Aspergillosis
5.2.2 Dermatophytosis
5.2.3 Candidiasis
5.2.4 Others
5.3 By Application
5.3.1 Powders
5.3.2 Ointments
5.3.5 Drugs
5.3.4 Pastes
6. Geographical Analysis
6.1 Europe
6.1.1 Introduction
6.1.2 U.K
6.1.3 Spain
6.1.4 Germany
6.1.5 Italy
6.1.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Alternaria
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer
8.3 Novartis
8.4 Sanofi-Aventis
8.5 Merck & Co.
8.6 Asperqillus
8.7 Kramer Laboratories
8.8 Bayer Healthcare
8.9 Enzon Pharmaceuticals
8.10 Glaxosmithkline Gilead
8.11 Abbott Laboratories
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
